Visium Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Visium Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-420,000	Closed	-$2.94M	–	505
2016 Q1	$2.94M	Sell	420,000 -20,000	-5%	-$144K	0.05%	345
2015 Q4	$3.54M	Hold	440,000	–	–	0.05%	334
2015 Q3	$3.63M	Sell	440,000 -10,000	-2%	-$99.3K	0.05%	350
2015 Q2	$5.19M	Sell	450,000 -25,000	-5%	-$346K	0.07%	273
2015 Q1	$8.01M	Buy	475,000 +25,000	+6%	+$462K	0.12%	182
2014 Q4	$8.89M	Buy	+450,000	New	+$6.61M	0.13%	147

Other funds holding XENE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

IPC

Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return

Visium Asset Management's XENE Position: Q2 2016 in Review

Visium Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2016, closing a stake of 420,000 shares — an estimated $2.94M sold.

Visium Asset Management first reported a position in XENE in Q4 2014 and held it in 6 quarters. The position peaked at $8.89M in Q4 2014. 21 funds tracked by Wall St. Rank hold XENE as of Q2 2016.

Visium Asset Management reported no remaining Xenon Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 420,000 Xenon Pharmaceuticals shares in Q2 2016, an estimated $2.94M.
Visium Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Visium Asset Management's Xenon Pharmaceuticals position peaked at $8.89M in Q4 2014.
21 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.